WO2003105762A3 - Methode de traitement de maladies avec du radium-225 - Google Patents

Methode de traitement de maladies avec du radium-225 Download PDF

Info

Publication number
WO2003105762A3
WO2003105762A3 PCT/US2003/018634 US0318634W WO03105762A3 WO 2003105762 A3 WO2003105762 A3 WO 2003105762A3 US 0318634 W US0318634 W US 0318634W WO 03105762 A3 WO03105762 A3 WO 03105762A3
Authority
WO
WIPO (PCT)
Prior art keywords
radium
treating disease
chelator
peptide
association
Prior art date
Application number
PCT/US2003/018634
Other languages
English (en)
Other versions
WO2003105762A2 (fr
Inventor
Kenneth R Givens
Original Assignee
Actinium Pharmaceuticals Ltd
Kenneth R Givens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinium Pharmaceuticals Ltd, Kenneth R Givens filed Critical Actinium Pharmaceuticals Ltd
Priority to AU2003248679A priority Critical patent/AU2003248679A1/en
Publication of WO2003105762A2 publication Critical patent/WO2003105762A2/fr
Publication of WO2003105762A3 publication Critical patent/WO2003105762A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une méthode de traitement de maladies, telles que par exemple le cancer des os, dans laquelle on administre une composition comprenant du radium-225, par exemple, du chlorure de radium. Le radium-225 peut être utilisé sous forme d'une espèce cationique, en association avec un chélateur ou en association avec un autre type de vecteur (par exemple, une molécule, un anticorps, un peptide, un analogue protéinique, une combinaison chélateur-anticorps, une combinaison peptide-anticorps, un composé fullerène associé ou un lipide).
PCT/US2003/018634 2002-06-14 2003-06-12 Methode de traitement de maladies avec du radium-225 WO2003105762A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003248679A AU2003248679A1 (en) 2002-06-14 2003-06-12 Treating disease using radium-225

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38880802P 2002-06-14 2002-06-14
US60/388,808 2002-06-14

Publications (2)

Publication Number Publication Date
WO2003105762A2 WO2003105762A2 (fr) 2003-12-24
WO2003105762A3 true WO2003105762A3 (fr) 2004-03-04

Family

ID=29736547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018634 WO2003105762A2 (fr) 2002-06-14 2003-06-12 Methode de traitement de maladies avec du radium-225

Country Status (2)

Country Link
AU (1) AU2003248679A1 (fr)
WO (1) WO2003105762A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005259258B2 (en) 2004-06-25 2010-11-25 The European Community, Represented By The European Commission Radionuclides for medical use
WO2017003908A1 (fr) 2015-06-30 2017-01-05 The Trustees Of Columbia University In The City Of New York Compositions à liaison avec du talc et leurs utilisations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015768A1 (fr) * 1992-02-11 1993-08-19 Nycomed Salutar, Inc. Utilisation de fullerenes dans des agents diagnostiques et/ou therapeutiques
US5248498A (en) * 1991-08-19 1993-09-28 Mallinckrodt Medical, Inc. Fullerene compositions for magnetic resonance spectroscopy and imaging
US5922302A (en) * 1993-05-17 1999-07-13 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US6143274A (en) * 1986-01-23 2000-11-07 Tweedle; Michael F. Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US6296831B1 (en) * 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US6338835B1 (en) * 1997-06-03 2002-01-15 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143274A (en) * 1986-01-23 2000-11-07 Tweedle; Michael F. Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5248498A (en) * 1991-08-19 1993-09-28 Mallinckrodt Medical, Inc. Fullerene compositions for magnetic resonance spectroscopy and imaging
WO1993015768A1 (fr) * 1992-02-11 1993-08-19 Nycomed Salutar, Inc. Utilisation de fullerenes dans des agents diagnostiques et/ou therapeutiques
US5922302A (en) * 1993-05-17 1999-07-13 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US6338835B1 (en) * 1997-06-03 2002-01-15 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US6296831B1 (en) * 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOLDMAN ET AL., TRANS. ANS, vol. 50, November 1985 (1985-11-01), pages 7 - 8, XP002970788 *
WASHIYAMA ET AL.: "Biodistribution of Ra-225 and their daughter nuclides in neptunium series", INT. SYMP. BIO-TRACE ELEM., 2002, XP002970789 *

Also Published As

Publication number Publication date
AU2003248679A8 (en) 2003-12-31
WO2003105762A2 (fr) 2003-12-24
AU2003248679A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
UA85993C2 (ru) Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
DK1161452T3 (da) Kovalent forbundne insulindimerer
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
PL336704A1 (en) Multivalent vaccine containing a mixed carrier
AU2002350592A8 (en) Ph-sensitive polymer
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
WO2004076644A3 (fr) Composition pour la delivrance d'un agent a une cellule cible et ses utilisations
AU2003217055A1 (en) Protein for use in hypoxia related conditions
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
RS20110024A (en) ANTIBODIES THAT BLOCK CRIPTO AND USE IT
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
SE9901875D0 (sv) Novel compounds
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
HK1064585A1 (en) Improved chelator conjugates.
DE60134274D1 (en) Complex enthaltend modafinil und cyclodextrin
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
HK1040983A1 (en) Quinones for treatment of diseases.
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
AU2003277280A1 (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease
GB9907571D0 (en) Compounds
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
WO2003105762A3 (fr) Methode de traitement de maladies avec du radium-225

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP